

**Department of Planning and Budget  
2026 General Assembly Session  
State Fiscal Impact Statement**

---

**PUBLISHED: 2/5/2026 10:21 AM**

**ORIGINAL**

**Bill Number:** HB1025

**Patron:** Walker

**Bill Title:** Access to investigational drugs, biological products, and devices; patient with severely debilitating condition.

**Bill Summary:** Allows a patient who has a severely debilitating condition, defined in the bill as a disease or condition that causes major irreversible morbidity, to access investigational drugs, biological products, and devices when certain criteria are met. Under current law, only a patient who has a terminal condition may access such drugs, products, and devices.

**Budget Amendment Necessary:** No

**Items Impacted:** None

**Fiscal Summary:** This bill is not expected to have a fiscal impact on state agencies.

**Fiscal Analysis:**

**Department of Medical Assistance Services (DMAS)**

Currently, investigational drugs are not a covered service in the state plan for medical assistance. The bill does not direct the agency to begin covering access to these drugs; therefore, there is no expected fiscal impact to the agency under the provisions of the bill.

**Department of Human Resource Management (DHRM)**

Under current law, patients with terminal conditions are able to access investigational drugs but insurers are not required to provide coverage for those drugs. DHRM notes that the state employee health plan does not cover investigational drugs for terminal drugs. Therefore, it is assumed that the state employee health plan would also not cover such drugs under the expanded provisions of the bill.

**Other:** -